Review of existence of and timing of National Drug Codes in OHDSI Network

**Version:** 0.1

**Authors:**

Erica A. Voss, MPH, Janssen Research and Development

Dmytry Dymshyts

Anna Ostropolets

Vojtech Huser

Christian Reich

**Date:** 16 March 2018

**Acknowledgment:** The analysis is based in part on work from the Observational Health Sciences and Informatics collaborative. OHDSI (<http://ohdsi.org>) is a multi-stakeholder, interdisciplinary collaborative to create open-source solutions that bring out the value of observational health data through large-scale analytics.

The authors declare the following disclosures: Dr. Ryan and Ms. Voss are employees of Janssen Research & Development.

# Table of contents

[1 Table of contents 2](#_Toc508881496)

[2 List of abbreviations 3](#_Toc508881497)

[3 Abstract 3](#_Toc508881498)

[4 Amendments and Updates 3](#_Toc508881499)

[5 Milestones 3](#_Toc508881500)

[6 Rationale and Background 3](#_Toc508881501)

[7 Study Objectives 3](#_Toc508881502)

[7.1 Primary Hypotheses 3](#_Toc508881503)

[7.2 Secondary Hypotheses 3](#_Toc508881504)

[7.3 Primary Objectives 3](#_Toc508881505)

[7.4 Secondary Objectives 3](#_Toc508881506)

[8 Research methods 3](#_Toc508881507)

[8.1 Study Design 3](#_Toc508881508)

[8.2 Data Source(s) 3](#_Toc508881509)

[8.3 Study population 4](#_Toc508881510)

[8.4 Outcomes 4](#_Toc508881511)

[8.5 Covariates 4](#_Toc508881512)

[8.5.1 Propensity score covariates 4](#_Toc508881513)

[9 Data Analysis Plan 4](#_Toc508881514)

[9.1 Calculation of time-at risk 4](#_Toc508881515)

[9.2 Model Specification 4](#_Toc508881516)

[9.2.1 Pooling effect estimates across databases 4](#_Toc508881517)

[9.3 Analyses to perform 4](#_Toc508881518)

[9.4 Output 4](#_Toc508881519)

[9.5 Evidence Evaluation 4](#_Toc508881520)

[10 Study Diagnostics 4](#_Toc508881521)

[10.1 Sample Size and Study Power 4](#_Toc508881522)

[10.2 Cohort Comparability 4](#_Toc508881523)

[11 Strengths and Limitations of the Research Methods 4](#_Toc508881524)

[12 Protection of Human Subjects 5](#_Toc508881525)

[13 Management and Reporting of Adverse Events and Adverse Reactions 5](#_Toc508881526)

[14 Plans for Disseminating and Communicating Study Results 5](#_Toc508881527)

[15 References 6](#_Toc508881528)

# List of abbreviations

TBD

# Abstract

TBD

# Amendments and Updates

|  |  |  |  |
| --- | --- | --- | --- |
| 0.1 | 16-MAR-2018 | E.Voss | First draft |

# Milestones

|  |  |
| --- | --- |
| Milestone | Planned / Estimated Date |
| TBD |  |
|  |  |
|  |  |

# Rationale and Background

National Drug Codes (NDC) is one of the main methods of codifying drugs in the United States thus the relationships mapping NDC codes to standard terminologies in the Observational Medical Outcomes Partnership (OMOP) Vocabulary play an important role when transforming US datasets into the OMOP Common Data Model (CDM). Working with NDCs is tricky as there is not one organization that manages the codes and therefore there is not one location to source the codes and their times of validity.

This study is designed to learn from the OHDSI Community what NDCs we may be missing in our OMOP Vocabulary and the years NDCs are active within data.

# Study Objectives

## Primary Hypotheses

TBD

## Secondary Hypotheses

N/A

## Primary Objectives

TBD

## Secondary Objectives

N/A

# Research methods

## Study Design

TBD

## Data Source(s)

TBD

## Study population

TBD

## Outcomes

N/A

## Covariates

### Propensity score covariates

N/A

# Data Analysis Plan

## Calculation of time-at risk

N/A

## Model Specification

N/A

### Pooling effect estimates across databases

N/A

## Analyses to perform

N/A

## Output

TBD

## Evidence Evaluation

N/A

# Study Diagnostics

## Sample Size and Study Power

N/A

## Cohort Comparability

N/A

# Strengths and Limitations of the Research Methods

TBD

# Protection of Human Subjects

TBD

# Management and Reporting of Adverse Events and Adverse Reactions

TBD

# Plans for Disseminating and Communicating Study Results

TBD

# References